Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China
· Delayed Price · Currency is CNY 17.92
+0.12 (0.67%)
May 13, 2025, 3:00 PM CST
SHA:688062 Revenue
Mabwell (Shanghai) Bioscience had revenue of 44.79M CNY in the quarter ending March 31, 2025, a decrease of -33.70%. This brings the company's revenue in the last twelve months to 177.01M, down -7.49% year-over-year. In the year 2024, Mabwell (Shanghai) Bioscience had annual revenue of 199.78M with 56.28% growth.
Revenue (ttm)
177.01M
Revenue Growth
-7.49%
P/S Ratio
40.45
Revenue / Employee
125.01K
Employees
1,416
Market Cap
7.16B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |